Document is current
Any future updates will be listed below
-
Authors
Arama, Eli
Cosentino, Katia
Czabotar, Peter E.
Gan, Boyi
Hartland, Elizabeth
Jiang, Xuejun
Kagan, Jonathan C.
Nagata, Shigekazu
Schroder, Kate
Sun, Liming
Xu, Daichao
Yuan, Junying
- License Information
-
More Information
Article History
First Online: 18 September 2025
Competing interests
: P.E.C. is an employee of the Walter and Eliza Hall Institute, which has an agreement with Genentech and AbbVie, and receives milestone and royalty payments related to Venetoclax. Employees of the Walter and Eliza Hall Institute may be eligible for financial benefits related to these payments. P.E.C. receives such a financial benefit as a result of previous research related to Venetoclax. X.J. is an inventor on patents related to autophagy and cell death, and he holds equity of and consults for Exarta Therapeutics and Lime Therapeutics. J.C.K. receives compensation from and holds equity in Corner Therapeutics, Larkspur Biosciences, MindImmune Therapeutics and Neumora Therapeutics. None of these relationships impacted this study. K.S. is a co-inventor on patent applications for NLRP3 inflammasome inhibitors which have been licensed to Inflazome, a company acquired by Roche. K.S. served on the Scientific Advisory Boards of Inflazome (Ireland), Quench Bio (USA) and Novartis (Switzerland). All other authors declare no competing interests.
